Iron bioavailability and cardiopulmonary function during ascent to very high altitude. by Holdsworth, D.A. et al.
Iron bioavailability and cardiopulmonary
function during ascent to very high
altitude
To the Editor:
More than one hundred million people reside worldwide at altitudes in excess of 2500 m above sea level. In the
millions more who sojourn at high altitude for recreational, occupational or military pursuits, hypobaric
hypoxia drives physiological changes affecting the pulmonary circulation, haematocrit and right ventricle (RV)
[1]. Coincident with these, maximal left ventricular (LV) stroke volume (SV) falls [2], with a reduction of 20%
reported after a 2-week stay at 4300 m [3]. A rise in heart rate (HR) compensates at rest and during submaximal
exercise but is insufficient during maximal intensity exercise, constraining maximal cardiac output (CO).
Previously, it was considered that a reduction in plasma volume or a direct effect of hypoxia on LV myocardial
contractility were probably responsible [4]. More recently it has been suggested that increased RV afterload may
be of greater importance [5].
Hypoxic pulmonary vasoconstriction (HPV) contributes significantly to increased RV work and pulmonary
hypertension during alveolar hypoxia [6]. In healthy iron-replete individuals, intravenous (i.v.) iron
attenuates HPV [7, 8], tending to reduce RV afterload. We hypothesised that i.v. iron would improve
cardiopulmonary function during ascent to very high altitude through this action upon the pulmonary
vasculature, with or without a direct effect on the heart.
We conducted a randomised, controlled, double-blind, clinical physiology study. 18 British Armed Forces
personnel (17 male, 1 female) volunteered; one was excluded because of abnormal baseline iron indices.
Participants were randomised to receive either 1 g ferric carboxymaltose (Ferinject), or saline control, as a
single infusion. 2 weeks later, participants flew to Kathmandu, Nepal, at an altitude of 1400 m, were driven
to 2600 m (day 4), trekked to 3800 m (day 5), 4100 m (day 7), and then 5100 m (day 10). Serial
measurements of iron indices, peripheral oxyhaemoglobin saturation (SpO2), and transthoracic
echocardiographic parameters (VividQ, GE, Boston, MA, USA) were recorded at rest.
Stroke volume was estimated by multiplying LV outflow tract (LVOT) velocity-time integral (VTI) by LVOT
cross-sectional area, and CO by multiplying SV and HR. Both were then normalised to body surface area in m2
(BSA; Mosteller formula).
Right ventricular systolic pressure (RVSP) was estimated from the peak velocity of the tricuspid
regurgitation jet [1, 5, 7–9]. The LV and RV indices of myocardial performance (LIMP and RIMP) and
tricuspid annular planar systolic excursion (TAPSE) were measured. Pulmonary vascular resistance (PVR)
was estimated using the Abbas method [9]. Between-group differences in responses were analysed using
mixed-effects modelling (SPSS Statistics version 25, IBM). Ethical approval was given by the Ministry of
Defence Research Ethics Committee, all participants provided written informed consent, and the study was
registered with ClinicalTrials.gov (NCT03707249).
The groups were well matched at baseline. Comparisons for the iron group versus controls were as follows:
mean±SD age 35.5±8.2 versus 36.1±7.7 years; body mass index 24.8±1.0 versus 24.6±2.0 kg·m−2; and BSA
2.02±0.06 versus 1.99±0.04 m2. No adverse infusion-related events occurred. One participant in the control
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group did not ascend beyond 4100 m due to severe gastrointestinal symptoms; all available data for this
participant were included in the analysis.
Changes in iron indices, haematological parameters and cardiopulmonary variables are illustrated in figure 1.
Ferritin and hepcidin were elevated in the iron group, with a corresponding reduction in the rise in both
erythropoietin and soluble transferrin receptor (sTfR).
The prior administration of iron significantly attenuated the progressive fall in SpO2 seen with increasing
altitude (absolute difference in desaturation 5.5%, 95% CI 2.5–8.4%; p<0.001). Iron also abolished the
normal fall in SV observed with increasing altitude. The mean between-group difference in the change in
stroke volume index (SVI) was 6.2 mL·m−2 (95% CI 0.31–12.2 mL·m−2; p=0.039).
In the control group, LIMP, RIMP and TAPSE all worsened significantly with increasing altitude. LIMP
rose by 0.08 (95% CI 0.003–0.16; p=0.043), RIMP rose by 0.31 (95% CI 0.24–0.38; p<0.001), and TAPSE
fell by 0.55 cm (95% CI 0.27–0.83 cm; p<0.001). When comparing the iron group with controls, the degree
of impairment in RIMP and TAPSE was reduced by 0.14 (95% CI 0.03–0.24; p=0.013) and 0.41 cm (95%
CI 0.01–0.82 cm; p=0.045), respectively. However, the iron group showed no difference in the deterioration
in LIMP (95% CI for between group difference −0.07–0.16; p=0.41) nor the rise in RVSP on ascent (95%
CI −7.6–4.0 mmHg; p=0.51).
Interestingly, we found that iron supplementation was associated with augmented SV in the absence of a
difference in RVSP. Had PVR remained similar in both groups, the higher SV of the iron group would be
expected to have associated with a higher RVSP. In fact, RVSP responses were similar and there appeared
to be a trend towards a lower PVR in the iron group, although this was not statistically significant (95% CI
−0.58–0.23 Wood units; p=0.38). However, a strong negative correlation was evident between the change
in SVI and the change in PVR (Pearson’s r=−0.72; p=0.003), implying a close relationship between
increased RV afterload and falling SV.
Reduced PVR might be a direct result of increased iron bioavailability, as previously described [7, 8], or
may result from improved oxyhaemoglobin saturation. The latter would also act to reduce HPV as the
result of a corresponding increase in mixed venous oxygen tension. The latter is a significant stimulus for
HPV, albeit less so than alveolar oxygen tension [10]. Both mechanisms are biologically plausible, as is the
putative mechanism for increased oxygenation in the iron group: that an iron-mediated reduction in HPV
promotes ventilation/perfusion matching. The finding that RV, but not LV, function was enhanced in the
group given iron also seems likely to reflect reduced RV work secondary to attenuated HPV and
consequently reduced PVR.
An alternative explanation would be that iron acted to augment the ventilatory response to hypobaric
hypoxia. We were not able to measure ventilation as part of the expedition. Whilst there is good reason to
believe iron bioavailability might affect pulmonary ventilation via an action on the hypoxia inducible
factor pathway within carotid body glomus cells [11], no human study has detected such a phenomenon
[8, 12]. Moreover, the expected direction of effect is for iron to diminish alveolar ventilation rather than
augment it.
The links between iron, erythropoiesis and oxygen homeostasis are complex [13]. Erythropoietin is under
transcriptional regulation by both hypoxia and iron [12], so the attenuated erythropoietin rise in the iron
group will reflect some combination of both a direct action of iron and improved renal oxygenation. The rise
in sTfR, levels of which reflect the balance between iron supply and erythropoietic activity [14], was similarly
attenuated in the iron group, reflecting some combination of greater iron bioavailability and lower
stimulation of the bone marrow by erythropoietin. Both iron and hypoxia regulate expression of hepcidin,
the key hormone regulating iron homeostasis; the effect of hypoxia is indirect, mediated downstream of
marrow stimulation [13]. The effect of prior iron infusion on iron bioavailability in the present study was so
marked that it lifted the heavy suppression of hepcidin seen at 5100 m in the control group.
A role for i.v. iron therapy is well established in chronic heart failure [15]. Our findings support the view
that manipulation of iron bioavailability should be explored more broadly in conditions that feature
increased PVR, ventilation/perfusion mismatch, or right heart dysfunction, including right heart failure,
FIGURE 1 Variation with altitude of iron indices, haematological parameters and cardiopulmonary physiological variables. Sea-level data were
acquired immediately prior to infusion of iron or saline. Data are plotted as mean±SEM. The p-values given are for the interaction between group
and altitude, that is, whether iron administration altered the change from sea level to maximum altitude. SpO2: peripheral oxyhaemoglobin
saturation; SVI: stroke volume index; TSat: transferrin saturation; Hb: haemoglobin concentration; sTfR: soluble transferrin receptor; CI: cardiac
index; RIMP and LIMP: RV and LV indices of myocardial performance (combined measures of the efficiency of ventricular filling and ejection;
higher values indicate more significant impairment); Epo: erythropoietin; RVSP: right ventricular systolic pressure; PVR: pulmonary vascular
resistance; TAPSE: tricuspid annular planar systolic excursion.
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acute pulmonary embolism, high altitude pulmonary oedema, adult congenital heart disease, chronic
thromboembolic pulmonary hypertension and COPD.
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